Clinical trials: Depressive Disorder NOS
Major Depressive Disorder, Posttraumatic Stress Disorder
Comparing Group Therapies for Veterans With Depression and PTSD
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective psychotherapy for individuals with depressive and PTSD. However, CBT is largely underutilized within Veteran Affairs Medical Centers (VAMCs) due to the cost…
- Trial name
- NCT03979040
- Testing
- Group Transdiagnostic Behavior Therapy, Group Disorder-Specific Therapy (G-DSTs)
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder…
- Trial name
- NCT01185340
- Testing
- LY2216684, SSRI
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 1,056 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.
- Trial name
- NCT03315793
- Testing
- Duloxetine Hydrochloride
- Where
- Japan
- Volunteers
- 149 people
- Sponsor
- Shionogi
Treatment Resistant Depression
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID KOR (NCT01913535)
- Testing
- CERC-501
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Premenstrual Dysphoric Disorder
Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
The purpose of this study is to compare a low dose oral contraceptive (OC) given continuously (every day for three months) with the same low dose oral contraceptive given in an interrupted regimen (one week of inactive placebo…
- Trial name
- PMDD (NCT00927095)
- Testing
- Continuous OC (EE/DROS), Intermittent OC (EE/DROS)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of North Carolina, Chapel Hill
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Major Depressive Disorder
Open-Label of SPN-820 in Adults With Major Depressive Disorder
This study will evaluate of the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
- Trial name
- NCT06235905
- Testing
- NV-5138
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Navitor Pharmaceuticals, Inc.
Major Depressive Disorder
Electroconvulsive Therapy Amplitude Titration
This study is focused on advancing ECT treatment for older adults with depressive disorders by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.
- Trial name
- NCT04621786
- Testing
- Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of New Mexico
Major Depression
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
The purpose of this study is to find out what parts of the brain have increased or decreased activity when people are depressed and how antidepressant medicine changes this activity in depressed patients.
- Trial name
- NCT00707863
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indiana University
Major Depressive Disorder
Lipopolysaccharide (LPS) Challenge in Depression
LPS Challenge in Individuals with Major Depressive Disorder
- Trial name
- NCT03142919
- Testing
- Lipopolysaccharide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Major Depressive Disorder
Treatment of Depression With Connectivity Guided Robotically Delivered rTMS
The purpose of this study is to determine the clinical effects (if any) of connectivity-guided repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD) to provide clues about the…
- Trial name
- NCT02802293
- Testing
- repetitive transcranial magnetic stimulation, robotic arm
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838876
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression
This study was conducted to understand the use of a mobile app (titled Pathway) to help patients track depression symptoms, medications, side effects, and goals in addition to the usual care with their doctor.
- Trial name
- NCT04891224
- Testing
- Pathway Platform mobile app
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Wake Forest University Health Sciences
Postpartum Depression
Escitalopram (Lexapro) for the Treatment of Postpartum Depression
The purpose of this study is to determine whether women with postpartum major depressive disorder (MDD) will experience a significant decrease in depressive symptoms from baseline over an eight-week treatment intervention with…
- Trial name
- LexaproPPD (NCT00833469)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Major Depressive Disorder, Nicotine Dependence
Treatment of Nicotine Dependence and Acute Depression
The purpose of this study is to assess the safety and feasibility of concurrent treatment of nicotine dependence (cigarette smoking) and acute depression.
- Trial name
- NCT00186446
- Testing
- bupropion and smoking cessation behavioral intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Major Depressive Disorder
A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs).
- Trial name
- NCT01250873
- Testing
- LY2216684, Sertraline
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company